Please contact us for more information or to learn if you are eligible to participate.
In this study we aim (1) to determine the tumor genomic landscape of NASH-associated Hepatocellular Carcinomas in patients in South Texas and, (2) to detect selected somatic mutations in plasma cfDNA in patients with NASH-associated Hepatocellular Carcinoma, using a custom-designed targeted sequencing panel.
Principal Investigator | Jose Almeda, MD |
Type of Trial | Prospective |